Lossius-Cott C, Annoh A, Bens M, Nietzsche S, Hoffmann B, Figge M
JBMR Plus. 2025; 9(3):ziae173.
PMID: 39906260
PMC: 11788565.
DOI: 10.1093/jbmrpl/ziae173.
Biojone E, Guido B, Cavalcante L, Dos Santos Junior A, de Pontes R, Furtado F
Front Pediatr. 2024; 12:1505060.
PMID: 39711880
PMC: 11658997.
DOI: 10.3389/fped.2024.1505060.
Herrera-Uribe J, Convery O, ALmohammadi D, Weinberg F, Stevenson N
Inflammation. 2024; .
PMID: 39460806
DOI: 10.1007/s10753-024-02163-7.
Moghtit F, Boughrara W, Dorgham S, Koriche I, Ouahba I, Ammour A
Mol Biol Res Commun. 2024; 13(3):175-182.
PMID: 38915455
PMC: 11194026.
DOI: 10.22099/mbrc.2024.49437.1955.
Maceckova D, Vankova L, Holubova M, Jindra P, Klieber R, Jandova E
Mol Biol Rep. 2024; 51(1):521.
PMID: 38625438
DOI: 10.1007/s11033-024-09452-2.
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.
Tecik M, Adan A
Onco Targets Ther. 2022; 15:1449-1478.
PMID: 36474506
PMC: 9719701.
DOI: 10.2147/OTT.S384293.
Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD.
Schwarz M, Rizzo S, Paz W, Kresinsky A, Thevenin D, Muller J
Front Oncol. 2022; 12:1017947.
PMID: 36452504
PMC: 9701752.
DOI: 10.3389/fonc.2022.1017947.
Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells.
Chueahongthong F, Tima S, Chiampanichayakul S, Dejkriengkraikul P, Okonogi S, Sasarom M
Pharmaceutics. 2022; 14(10).
PMID: 36297550
PMC: 9610626.
DOI: 10.3390/pharmaceutics14102115.
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.
Ge S, Liu S, Xue S
Front Oncol. 2022; 12:996438.
PMID: 36185253
PMC: 9515417.
DOI: 10.3389/fonc.2022.996438.
Genetic Background of Polycythemia Vera.
Regimbeau M, Mary R, Hermetet F, Girodon F
Genes (Basel). 2022; 13(4).
PMID: 35456443
PMC: 9027017.
DOI: 10.3390/genes13040637.
Design and Synthesis of New Thiophene/Thieno[2,3-]pyrimidines along with Their Cytotoxic Biological Evaluation as Tyrosine Kinase Inhibitors in Addition to Their Apoptotic and Autophagic Induction.
Elmongy E, Attallah N, Altwaijry N, AlKahtani M, Henidi H
Molecules. 2022; 27(1).
PMID: 35011354
PMC: 8746632.
DOI: 10.3390/molecules27010123.
CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia.
Karnan S, Hanamura I, Ota A, Takasugi S, Nakamura A, Takahashi M
Cell Death Discov. 2021; 7(1):121.
PMID: 34035227
PMC: 8149417.
DOI: 10.1038/s41420-021-00446-8.
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Eguchi M, Minami Y, Kuzume A, Chi S
Biomedicines. 2020; 8(8).
PMID: 32722298
PMC: 7459983.
DOI: 10.3390/biomedicines8080245.
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X
J Hematol Oncol. 2020; 13(1):103.
PMID: 32718354
PMC: 7384229.
DOI: 10.1186/s13045-020-00924-z.
Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis.
Chen S, Chen Y, Zhu Z, Tan H, Lu J, Qin P
Int J Med Sci. 2020; 17(9):1269-1280.
PMID: 32547322
PMC: 7294926.
DOI: 10.7150/ijms.46441.
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H, Kawashima N, Ishikawa Y
Cancer Sci. 2019; 111(2):312-322.
PMID: 31821677
PMC: 7004512.
DOI: 10.1111/cas.14274.
Direct role of FLT3 in regulation of early lymphoid progenitors.
Zriwil A, Boiers C, Kristiansen T, Wittmann L, Yuan J, Nerlov C
Br J Haematol. 2019; 183(4):588-600.
PMID: 30596405
PMC: 6492191.
DOI: 10.1111/bjh.15578.
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D, Murray H, McLachlan T, Alvaro F, Enjeti A, Verrills N
Int J Mol Sci. 2018; 19(10).
PMID: 30332834
PMC: 6214138.
DOI: 10.3390/ijms19103198.
Human Cytomegalovirus Encodes a Novel FLT3 Receptor Ligand Necessary for Hematopoietic Cell Differentiation and Viral Reactivation.
Crawford L, Kim J, Collins-McMillen D, Lee B, Landais I, Held C
mBio. 2018; 9(2).
PMID: 29691342
PMC: 5915732.
DOI: 10.1128/mBio.00682-18.
Acute Myeloid Leukaemia: New Targets and Therapies.
Brown G, Marcinkowska E
Int J Mol Sci. 2017; 18(12).
PMID: 29189736
PMC: 5751180.
DOI: 10.3390/ijms18122577.